Payment overview · 2025
General Payments
$1,425.62
75 reported records · 24 companies
Healthcare provider profile · identity verified
Bennett Todd Baquet, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LAFAYETTE, LA · NPI 1073563631
Verified facts
What the public records show
CMS Open Payments records show Bennett Todd Baquet, M.D. received $1,425.62 in general payments during 2025 across 75 reported records.
Dexcom, Inc. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Prolia, Tymlos.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 939 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 660 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Tymlos by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $332.65 | 23.3% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $179.14 | 12.6% | 13 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $138.86 | 9.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $87.23 | 6.1% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $85.43 | 6.0% | 6 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $85.33 | 6.0% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $71.95 | 5.0% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$67.45 | 4.7% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $56.20 | 3.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.31 | 2.5% | 2 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $34.02 | 2.4% | 2 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $32.87 | 2.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.77 | 1.9% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.71 | 1.7% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $21.84 | 1.5% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $18.58 | 1.3% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.69 | 1.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.11 | 1.2% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $16.58 | 1.2% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.41 | 1.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.26 | 1.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.0% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $14.58 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.05 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,425.62 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $332.65 | 18 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $138.86 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $87.67 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $87.23 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $85.43 | 6 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $85.43 | 6 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $85.43 | 6 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $85.33 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $71.95 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $67.45 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $56.20 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $54.30 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.17 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $37.17 | 3 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.77 | 2 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $24.71 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $17.69 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 939 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 660 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 26 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
26 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
939 | 169 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
50 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
660 | 152 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2458 | 481 |
| Jardiance | Empagliflozin | 939 | 169 |
| Liothyronine Sodium | Liothyronine Sodium | 861 | 178 |
| Glimepiride | Glimepiride | 793 | 190 |
| Metformin Hcl | Metformin Hcl | 755 | 168 |
| Ozempic | Semaglutide | 660 | 152 |
| Synthroid | Levothyroxine Sodium | 575 | 115 |
| Mounjaro | Tirzepatide | 522 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 469 | 125 |
| Methimazole | Methimazole | 421 | 90 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 386 | 101 |
| Pioglitazone Hcl | Pioglitazone Hcl | 377 | 94 |
| Metformin Hcl Er | Metformin Hcl | 375 | 92 |
| Tresiba Flextouch U-100 | Insulin Degludec | 372 | 99 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 355 | 124 |
| Novolog Flexpen | Insulin Aspart | 337 | 92 |
| Trulicity | Dulaglutide | 309 | 65 |
| Alendronate Sodium | Alendronate Sodium | 297 | 61 |
| Cinacalcet Hcl | Cinacalcet Hcl | 245 | 37 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 229 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 216 | 50 |
| Testosterone Cypionate | Testosterone Cypionate | 195 | 60 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 187 | 51 |
| Lisinopril | Lisinopril | 176 | 44 |
| Novolog | Insulin Aspart | 170 | 50 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 28 |
| Farxiga | Dapagliflozin Propanediol | 134 | 19 |
| Ezetimibe | Ezetimibe | 125 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 117 | 24 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 114 | 37 |
| Gabapentin | Gabapentin | 112 | 27 |
| Losartan Potassium | Losartan Potassium | 106 | 32 |
| Humalog Kwikpen U-100 | Insulin Lispro | 99 | 31 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 96 | 19 |
| Simvastatin | Simvastatin | 96 | 19 |
| Januvia | Sitagliptin Phosphate | 86 | 14 |
| Hydrocortisone | Hydrocortisone | 82 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 78 | 27 |
| Droplet Pen Needle | Pen Needle, Diabetic | 78 | 25 |
| Calcitriol | Calcitriol | 71 | 17 |
| Desmopressin Acetate | Desmopressin Acetate | 61 | suppressed |
| Repaglinide | Repaglinide | 61 | 24 |
| Potassium Chloride | Potassium Chloride | 57 | 12 |
| Armour Thyroid | Thyroid,pork | 55 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 52 | 15 |
| Fiasp | Insulin Aspart (Niacinamide) | 50 | 19 |
| Insulin Lispro | Insulin Lispro | 49 | 11 |
| Invokana | Canagliflozin | 49 | suppressed |
| Lovastatin | Lovastatin | 47 | suppressed |
| Vascepa | Icosapent Ethyl | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 11 |
| Fenofibrate | Fenofibrate | 44 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 44 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Humalog | Insulin Lispro | 43 | 13 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 42 | suppressed |
| Xyosted | Testosterone Enanthate | 42 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 41 | suppressed |
| Glipizide | Glipizide | 40 | 15 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 39 | suppressed |
| Novolin R | Insulin Regular, Human | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Np Thyroid | Thyroid,pork | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 33 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 29 | suppressed |
| Prednisone | Prednisone | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Prolia | Denosumab | 26 | 18 |
| Somatuline Depot | Lanreotide Acetate | 26 | suppressed |
| Insulin Aspart | Insulin Aspart | 25 | suppressed |
| Cabergoline | Cabergoline | 24 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 24 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 21 |
| Genotropin | Somatropin | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Acarbose | Acarbose | 21 | suppressed |
| Cycloset | Bromocriptine Mesylate | 21 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Tymlos | Abaloparatide | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Unithroid | Levothyroxine Sodium | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cortef | Hydrocortisone | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Lyumjev | Insulin Lispro-Aabc | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Somavert | Pegvisomant | 12 | suppressed |
| Admelog | Insulin Lispro | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,425.62 · 75 records | Dexcom, Inc. | Bimzelx, CRENESSITY, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IMCIVREE, JARDIANCE, LUPKYNIS, MINIMED 780G, MYCAPSSA, Omnipod, Ozempic, PROLIA, PURIFIED CORTROPHIN GEL, RECORLEV, RENFLEXIS, REZDIFFRA, TAVNEOS, TEPEZZA, TWIIST, TZIELD, Tymlos, Yorvipath, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error